The role of the University of Connecticut/UConn Health’s Stem Cell Research Oversight Committee (SCRO) is to ensure that human embryonic stem cell (hESC) and human induced pluripotent stem cell (iPSC) research is well-justified and that inappropriate and/or unethical research is not conducted. Its mandate is to provide oversight of ethical issues related to the derivation and research use of human stem cell lines at all schools, colleges, campuses, and research arms of the University of Connecticut/UConn Health regardless of the source of funding, and to review all proposals from University of Connecticut/UConn Health investigators funded by the State of Connecticut’s Regenerative Medicine Research Fund. Review by the SCRO committee supplements but does not replace the usual reviews for compliance with federal, state, and local regulations (e.g., reviews by Institutional Animal Care and Use Committees (IACUC), Institutional Review Boards (IRB), Institutional Biological Safety Committees (IBC), etc.).
All research projects in the following categories are required to obtain SCRO approval before acquiring cells or cell lines and commencing research:
- All stem cell research projects funded by the State of Connecticut, including those that do not use human embryonic stem cells;
- All stem cell research involving human embryonic stem cells, pluripotent cells, and their derivatives;
- All stem cell research involving human gametes and human embryos;
- in vitro human induced pluripotent stem cell research involving the generation of gametes, embryos, or other types of totipotent cells;
- in vivo human induced pluripotent stem cell research involving implantation of human cells into prenatal animals or into the central nervous system of post-natal animals.
For more information, visit the SCRO web pages at UConn Health.